We’re at a pivotal moment in psychedelic history. Millions of people, who have read about the rigorous, double-blind clinical trials investigating psilocybin and other compounds for mental health, are interested in learning more. And yet, there remain few trusted, accessible resources for people to learn about psychedelics. That’s why we started DoubleBlind.
DoubleBlind has a joint column on Rolling Stone, where we report on the latest developments in the worlds of psychedelic drug development and policy. We’ve been invited to speak at dozens conferences on the psychedelic movement, including PsyTech, The Mt. Tam Psilocybin Summit, Horizons Convention, and SXSW. We’ve also been featured in and interviewed by numerous publications as experts, including Forbes, Bustle, Business Insider, and VICE.
About Our Contributors
DoubleBlind is devoted to upholding the most rigorous journalistic standards. All data and research cited are fact-checked for rigor and accuracy. We give the full picture, including information on harm reduction and potential risks. All of our articles and webinars feature leading, qualified experts such as Dr. Rick Strassman, associate clinical professor of psychiatry at the University of New Mexico School of Medicine; Dr. James Fadiman, a psychedelic pioneer who has been doing research in the field for more than five decades; mycologist Paul Stamets, author of five mycology books most known for his popular TED talk; Rick Doblin, Ph.D., the founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies; Dr. Jeffrey Becker, a UCLA-trained ketamine researcher and Chief Medical Officer at Bexson Biomedical, among dozens of other scientists and therapists at prominent institutions like Johns Hopkins, New York University, Imperial College London, and beyond.
All of DoubleBlind’s regular contributors are highly trained journalists with extensive experience covering psychedelics, cannabis, and plant medicines for news outlets including The New York Times, VICE, Rolling Stone, The Guardian, Vanity Fair, and beyond.
It is important to us that when you get information from our site, you know that you can trust it. And we are always available to answer any follow-up questions you may have. You can contact us at: [email protected].